- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05142345
Care Transition Intervention for Hospitalized Patients With Advanced Cancer
Randomized Trial of a Care Transition Intervention for Hospitalized Patients With Advanced Cancer
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
To address the rising incidence and burden of hospital readmissions for patients with advanced cancer, the investigators developed a population-specific care transition intervention based upon the scholarly literature and our qualitative study. The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology NP within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
From 01/07/21 to 05/28/21, the investigators conducted a pilot trial of CONTINUUM in 48 patients with advanced cancer recently discharged from the Massachusetts General Hospital Cancer Center (NCT04640714). The investigators found that the intervention was feasible and acceptable in our population.
The investigators are now conducting a randomized controlled trial of the CONTINUUM intervention versus standard of care, to study whether CONTINUUM improves patients' confidence in managing their health condition, as measured by the Patient Activation Measure-13. The investigators will also assess the efficacy of CONTINUUM for improving patient satisfaction with clinician communication, and physical and psychological symptom burden. Lastly, the investigators will explore the effect of the intervention on hospital readmissions within 30-days.
Study procedures include random assignment to either the CONTINUUM intervention or standard oncology care following hospital discharge, questionnaires and medical record data collection.
Participants are expected to be on the study for up to 40 days after hospital discharge.
It is anticipated that about 286 people will take part in this research study.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jennifer S Temel, MD
- Telefonnummer: (617) 724-4000
- E-post: jtemel@partners.org
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital Cancer Center
-
Ta kontakt med:
- Jennifer S Temel, MD
- Telefonnummer: 617-724-4000
- E-post: jtemel@mgh.harvard.edu
-
Hovedetterforsker:
- Jennifer S Temel, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age >= 18 years
- First unplanned admission to the oncology service at Massachusetts General Hospital (MGH) since diagnosis of advanced cancer
- Known diagnosis of advanced breast, thoracic, genitourinary, or gastrointestinal cancer
- Receiving ongoing oncology care at MGH
- Verbal fluency in English
- Internet/wifi or telephone access
- Residing in Massachusetts at the time of hospital discharge
Exclusion Criteria:
- Admitted electively
- Discharged to a location other than home or expired during admission
- Discharged with hospice services
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: CONTINUUM Intervention Post-Hospital Discharge
Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
|
The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
|
Aktiv komparator: Usual Care Post-Hospital Discharge
Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences.
Participants will complete questionnaires about their cancer and care.
|
Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Patients' Confidence in Managing their Health Condition using the Patient Activation Measure-13 (PAM-13)
Tidsramme: Baseline to 10-15 days after hospital discharge
|
Compare change in the PAM-13 from baseline to 10-15 days post-discharge between study groups.
The PAM-13 is scored 0-100 with higher scores indicating greater confidence in managing one's health condition.
|
Baseline to 10-15 days after hospital discharge
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Quality of Communication using the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Communication subscale
Tidsramme: Up to 10-15 days after hospital discharge
|
Compare differences in CAHPS-Communication at up to 10-15 days post-discharge between study groups.
CAHPS-Communication has a composite score (score range 0-20) with higher scores indicating better satisfaction.
As recommended by CAHPS, we will also analyze specific differences in CAHPS-Communication individual items, which relate to patients' assessment of whether clinicians discussed 1) illness course expectations, 2) what is most important to the patient, and 3) how the treatment plan should match what is most important to the patient.
These items are scored as "Yes" vs. "No" responses.
|
Up to 10-15 days after hospital discharge
|
Symptom Burden using the Edmonton Symptom Assessment Scale (ESAS-r)
Tidsramme: Baseline to 10-15 days after hospital discharge
|
Compare change in the Edmonton Symptom Assessment System-Revised (ESAS-r) total score and physical sub-scale between baseline and 10-15 days of discharge between study groups.
Scores on the ESAS-r range from 0-100 with higher scores indicating worse symptom burden.
Scores on the ESAS-Physical sub-scale range from 0-70 with higher scores indicating worse symptom burden.
|
Baseline to 10-15 days after hospital discharge
|
Psychological Symptoms using the Patient Health Questionnaire-4 (PHQ-4)
Tidsramme: Baseline to 10-15 days after hospital discharge
|
Compare change in the Patient Health Questionnaire-4 (PHQ-4) between baseline and 10-15 days of discharge between study groups.
The PHQ-4 is a 4-item tool that contains two 2-item subscales assessing depression and anxiety symptoms.
Both subscales and the composite PHQ-4 score can also be evaluated continuously, with higher scores indicating worse psychological distress.
Scores on each subscale range from 0 to 6.
|
Baseline to 10-15 days after hospital discharge
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
30-day Hospital Readmissions
Tidsramme: Up to 30 days after discharge
|
Compare hospital readmissions within 30 days of discharge between study groups.
|
Up to 30 days after discharge
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Jennifer S Temel, MD, Massachusetts General Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 21-501
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på CONTINUUM Intervention
-
American Medical SystemsFullført
-
Kathmandu University School of Medical SciencesUkjentDiabetes mellitus, type 2
-
American Medical SystemsFullført
-
Rehabilitation Hospital of IndianaRekruttering
-
Stanford UniversityBill and Melinda Gates FoundationFullførtBarn | Svangerskap | Spedbarn | Ernæring | Helse
-
Institut de cancérologie Strasbourg EuropeContinuum Plus Santé; Plateforme nationale qualité de vie et cancer; WeShareRekrutteringBrystneoplasmer | Lungeneoplasmer | Prostatiske neoplasmer | Kolorektale neoplasmerFrankrike
-
Thomas Jefferson UniversityRekrutteringProstata karsinomForente stater
-
Oregon Research InstituteFullført
-
Sarah BlaylockVA Office of Research and DevelopmentFullførtFalle | LavsynForente stater
-
Tel Aviv UniversityFullført